Insulet extends NXP purchase agreement and amends pricing and volume terms
Insulet Corporation and NXP USA, Inc. signed a 2026 Addendum on January 29, 2026, effective January 1, 2026, to their 2017 Purchase Agreement. The addendum extends the agreement's term and changes terms on pricing, product volume, and product order flexibility. The filing does not disclose the specific new terms or financial amounts, as parts of the exhibit are omitted as confidential.
Key points
- Addendum signed January 29, 2026, effective January 1, 2026
- Extends the term of the October 12, 2017 Purchase Agreement, as amended
- Amends pricing, product volume, and product order flexibility terms
- Exhibit 10.1 filed with portions omitted as confidential; no dollar figures disclosed
The filing
Written by AI on Nov 8, 2026, 12:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 03, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.